Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEMadrasinCat.No.:HY-100236CASNo.:374913-63-0Synonyms:DDD00107587分?式:C??H??N?O?分?量:311.34作?靶點:Others作?通路:Others儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數據體外實驗DMSO:2mg/mL(6.42mM;Needultrasonic)H2O:<0.1mg/mL(insoluble)MassSolvent1mg5mg10mgConcentration制備儲備液1mM3.2119mL16.0596mL32.1192mL5mM0.6424mL3.2119mL6.4238mL10mM---------請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內使?，-20°C儲存時，請在1個?內使?。BIOLOGICALACTIVITY?物活性Madrasin(DDD00107587)?種剪接抑制劑，可在體外阻?剪接中間體和產物的形成，并?擾剪接體組裝途徑中的?個或多個早期步驟。Madrasin還能在體外抑制pre-mRNA的剪接，并修飾細胞中內性pre-mRNA1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE的剪接。IC50&Targetpre-mRNAsplicing[1]體外研究Madrasin(10-30μM;4-24hours;HeLacells)treatmentinhibitsthesplicingofeachoftheRIOK3,BRD2,andHsp40,MCL1,CCNA2,AURKAandp27pre-mRNAsinbothHeLaandHEK293cells[1].Madrasin(10-30μM;4-24hours;HeLaandHEK293cells)treatmentshowsadose-andtime-dependentinhibitoryeffectoncellcycleprogression[1].RT-PCR[1]CellLine:HeLacellsConcentration:10μM,20μM,or30μMIncubationTime:4hours,8hours,or24hoursResult:Increasedininhibitionofpre-mRNAsplicing.CellCycleAnalysis[1]CellLine:HeLaandHEK293cellsConcentration:10μM,20μM,or30μMIncubationTime:4hours,8hours,or24hoursResult:Inthepresenceof10μM8hoursaftertreatment,theproportionofcellsinG2,M,andSphasesincreased,withaconcomitantdecreaseinthenumberofG1phasecells.Thiseffectincreasedovertime,with>40%ofcellsinG2andMphaseand>50%inSphase24hours.戶使?本產品發表的科研?獻?NucleicAcidsRes.2019Sep5;47(15):8239-8254.?Theranostics.2022Jul11;12(12):5451-5469.?JMolMed(Berl).2019Aug;97(8):1183-1193.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].AndreaPawelleketal.IdentificationofSmallMoleculeInhibitorsofPre-mRNASplicing.JBiolChem,2014Dec12,289(50):34683-34698.McePdfHeight2/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemECaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseo